• Overview
  • Eligibility
  • More info
  • Locations

A Phase I Study To Assess The Absolute Bioavailability Of A Single Oral Dose Of AZD0284 And To Assess The Pharmacokinetics Of A Single Intravenous Microdose Of [14C]AZD0284 In Healthy Subjects. (NCT03029741)

The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. It occurs when skin cells are replaced more quickly than usual. The seriousness of psoriasis varies greatly from person to person. For some people it is a minor irritation, but for others it can have a major impact on their quality of life. . The purpose of the study is to determine how much of AZD0284 is taken up by the body. The safety and tolerability of the drug will also be assessed. It is hoped that the study drug will improve the management of psoriasis.
  • Drug: AZD0284
    Subjects will receive a single oral dose of 4 to 120 mg AZD0284 oral suspension 5 mg/mL in the fasted state
    • Drug: [14C]AZD0284
      Following administration of the AZD0284 oral suspension subjects will receive an IV infusion of 20 μg [14C]AZD0284 solution
      Ages eligible for Study
      18 Years to 65 Years
      Genders eligible for Study
      Accepts Healthy Volunteers
      Accepts Healthy Volunteers
      The study is a Phase I, single centre, open-label, non-randomized, single dose study performed in 6 healthy male subjects aged 18 to 65 years, inclusive. The study will assess the absolute bioavailability of a single oral dose of AZD0284 and the pharmacokinetics (PK) of a single intravenous (IV) microdose of [14C]AZD0284 in healthy male and female subjects. Oral AZD0284 and [14C] AZD0284 intravenous solution are referred to as the investigational products in this study.

      A screening visit to assess the eligibility of the healthy male and female subjects will occur within 28 days of the administration of the investigational product. Screening assessments will include medical history, inclusion/exclusion criteria, demographic data, weight and height, vein assessment, physical examination, blood samples for haematology, clinical chemistry and virology, blood test to confirm post-menopausal status (if female and of non-childbearing potential), blood test to confirm no history of tuberculosis, urine sample for urinalysis, urine test for pregnancy (if female and of childbearing potential) drug screen, alcohol breath test, carbon monoxide (CO) breath test, heart monitoring using ECG, vital signs (blood pressure, heart rate) Study related procedures will only be performed after signing of the Informed Consent Form.

      The healthy male and female subjects will be admitted to the study centre the day before administration of the investigational product (Day -1). On Day 1, subjects will be dosed with a single oral dose of 4 to 120 mg AZD0284 oral suspension (Regimen A) followed by 20 μg [14C]AZD0284 solution for IV infusion (Regimen B) beginning 3 hours after the oral dose has been administered. The IV microdose will be infused over 15 minutes and the end of the infusion is expected to be around the predicted tmax of Regimen A.

      The subjects will remain in the study centre until the 48 hour post dose PK blood sample is obtained. A follow up visit will occur 5 to 7 days after dosing and will include PK and routine safety assessments.

      1 locations

      United Kingdom (1)
      • Research Site
        Not specified
        Nottingham, United Kingdom
      20 February, 2017
      11 April, 2017
      A girl giving information about available additional trials.

      FindMeCure helps you find, understand and join clinical trials from all over the world.

      There are more clinical trials for your condition!